APA (7th ed.) Citation

Kagawa, Y., Nosaki, K., Matsumoto, S., Kato, T., Nakamura, A., Shingyoji, M., . . . Goto, K. (2022). MO45-1 Osimertinib vs. erlotinib + bevacizumab or ramucirumab for EGFR mutated NSCLC; a retrospective study from LC-SCRUM-Asia. Annals of Oncology, 33, S510. https://doi.org/10.1016/j.annonc.2022.05.214

Chicago Style (17th ed.) Citation

Kagawa, Yosuke, et al. "MO45-1 Osimertinib Vs. Erlotinib + Bevacizumab or Ramucirumab for EGFR Mutated NSCLC; a Retrospective Study from LC-SCRUM-Asia." Annals of Oncology 33 (2022): S510. https://doi.org/10.1016/j.annonc.2022.05.214.

MLA (9th ed.) Citation

Kagawa, Yosuke, et al. "MO45-1 Osimertinib Vs. Erlotinib + Bevacizumab or Ramucirumab for EGFR Mutated NSCLC; a Retrospective Study from LC-SCRUM-Asia." Annals of Oncology, vol. 33, 2022, p. S510, https://doi.org/10.1016/j.annonc.2022.05.214.